Hua Xia Shi Bao·2025-08-28 04:19Core Viewpoint - Foreign capital is accelerating its entry into the A-share market, particularly favoring small-cap stocks in the consumer and pharmaceutical sectors, as evidenced by significant investments in companies like Anji Food [2][4][10]. Company Performance - Anji Food reported a revenue of 309 million yuan for the first half of the year, marking an 8.54% year-on-year increase, while net profit attributable to shareholders reached 13.79 million yuan, up 58.61% [2]. - The company has seen a complete turnover in its top ten shareholders, with seven new foreign institutional investors entering the list, indicating strong foreign interest despite its relatively modest market capitalization of under 3 billion yuan [2][4]. Foreign Investment Trends - A notable trend is the influx of foreign investors into small-cap stocks, particularly in the consumer and pharmaceutical sectors, with many companies seeing foreign ownership exceeding 24% [3][4]. - Specific companies like Siyuan Electric and Huaming Equipment have attracted significant foreign investment, with Siyuan Electric's foreign ownership reaching 26.83% [4][5]. - The overall sentiment among foreign investors is driven by expectations of U.S. interest rate cuts, favorable economic policies in China, and the relative undervaluation of A-shares compared to U.S. and European stocks [4][9]. Market Dynamics - The A-share market is witnessing a shift as foreign investors are increasingly targeting undervalued small-cap stocks, particularly in the consumer and pharmaceutical sectors, as part of a broader strategy to capitalize on China's economic recovery [4][7]. - High-profile foreign institutions such as Morgan Stanley and UBS have been actively increasing their stakes in various small-cap companies, indicating a strategic focus on potential growth areas within the A-share market [6][9]. Sector Focus - The consumer and pharmaceutical sectors are particularly appealing to foreign investors, with companies like Anji Food and various small-cap pharmaceutical firms seeing increased foreign participation [2][9]. - Additionally, "中字头" (state-owned enterprises) and large-cap blue-chip stocks remain a staple in foreign portfolios, but there is a growing interest in smaller, high-potential companies as well [7][8].